INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has successfully closed its previously announced registered direct offering. The company sold 3,000,000 shares of common stock at $6.30 per share, raising approximately $19 million in gross proceeds before deducting fees and expenses.
The offering was priced at-the-market under Nasdaq rules and was conducted through A.G.P./Alliance Global Partners as the sole placement agent. The company plans to utilize the net proceeds for working capital purposes and general corporate procedures. The offering was executed under an effective shelf registration statement on Form S-3.
INmune Bio (NASDAQ: INMB), un'azienda in fase clinica specializzata in infiammazione e immunologia, ha completato con successo la sua offerta diretta registrata precedentemente annunciata. La società ha venduto 3.000.000 di azioni ordinarie a 6,30 $ per azione, raccogliendo circa 19 milioni di dollari di proventi lordi prima delle commissioni e delle spese.
L'offerta è stata valutata al prezzo di mercato secondo le regole Nasdaq ed è stata condotta tramite A.G.P./Alliance Global Partners come unico agente di collocamento. L'azienda intende utilizzare i proventi netti per il capitale circolante e per le procedure aziendali generali. L'offerta è stata eseguita nell'ambito di una dichiarazione di registrazione a scaffale efficace sul modulo S-3.
INmune Bio (NASDAQ: INMB), una empresa en etapa clínica dedicada a la inflamación e inmunología, ha cerrado con éxito su oferta directa registrada previamente anunciada. La compañía vendió 3.000.000 de acciones comunes a $6.30 por acción, recaudando aproximadamente $19 millones en ingresos brutos antes de deducir comisiones y gastos.
La oferta se valoró al precio de mercado según las normas de Nasdaq y se realizó a través de A.G.P./Alliance Global Partners como único agente colocador. La empresa planea utilizar los ingresos netos para capital de trabajo y procedimientos corporativos generales. La oferta se ejecutó bajo una declaración de registro efectiva en el Formulario S-3.
INmune Bio (NASDAQ: INMB)는 임상 단계의 염증 및 면역학 회사로서, 이전에 발표한 등록 직접 공모를 성공적으로 마감했습니다. 회사는 3,000,000주의 보통주를 주당 $6.30에 판매하여 수수료 및 비용 공제 전 약 1,900만 달러의 총 수익을 확보했습니다.
이번 공모는 Nasdaq 규정에 따라 시장 가격으로 책정되었으며, 단독 배정 대리인인 A.G.P./Alliance Global Partners를 통해 진행되었습니다. 회사는 순수익을 운전자본 및 일반 기업 운영에 사용할 계획입니다. 이 공모는 Form S-3의 유효한 선반 등록 명세서 하에 실행되었습니다.
INmune Bio (NASDAQ : INMB), une société en phase clinique spécialisée dans l'inflammation et l'immunologie, a clôturé avec succès son offre directe enregistrée précédemment annoncée. La société a vendu 3 000 000 d'actions ordinaires au prix de 6,30 $ par action, levant environ 19 millions de dollars de produit brut avant déduction des frais et dépenses.
L'offre a été évaluée au prix du marché selon les règles du Nasdaq et a été réalisée par l'intermédiaire d'A.G.P./Alliance Global Partners en tant qu'agent de placement unique. La société prévoit d'utiliser le produit net pour les besoins en fonds de roulement et les procédures générales de l'entreprise. L'offre a été exécutée dans le cadre d'une déclaration d'enregistrement en vigueur sur le formulaire S-3.
INmune Bio (NASDAQ: INMB), ein klinisch tätiges Unternehmen im Bereich Entzündungen und Immunologie, hat seine zuvor angekündigte direkte registrierte Platzierung erfolgreich abgeschlossen. Das Unternehmen verkaufte 3.000.000 Stammaktien zu je 6,30 $ pro Aktie und erzielte damit vor Abzug von Gebühren und Ausgaben einen Bruttoerlös von etwa 19 Millionen Dollar.
Das Angebot wurde gemäß den Nasdaq-Regeln zum Marktpreis bewertet und über A.G.P./Alliance Global Partners als alleinigen Platzierungsagenten durchgeführt. Das Unternehmen plant, die Nettoerlöse für das Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Das Angebot wurde im Rahmen einer wirksamen Shelf-Registration auf Formular S-3 durchgeführt.
- Successfully raised $19 million in gross proceeds through stock offering
- Offering was priced at-the-market under Nasdaq rules, indicating fair market value
- Proceeds will strengthen working capital position
- Dilution of existing shareholders through issuance of 3,000,000 new shares
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of
The gross proceeds from the Offering are approximately
A.G.P./Alliance Global Partners acted as sole placement agent for the Offering.
The Offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 279036) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the Offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™), and INKmune®™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Company Contact:
David Moss
Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ
How much capital did INmune Bio (INMB) raise in its June 2025 offering?
What is the price per share for INmune Bio's (INMB) June 2025 stock offering?
How many new shares did INmune Bio (INMB) issue in the June 2025 offering?
How will INmune Bio (INMB) use the proceeds from the June 2025 offering?
Who was the placement agent for INmune Bio's (INMB) June 2025 offering?
